Ignite Creation Date:
2024-05-05 @ 11:28 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00059982
Status:
COMPLETED
Last Update Posted:
2013-06-24
First Post:
2003-05-06
Brief Title:
Perifosine in Treating Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
Sponsor:
Eastern Cooperative Oncology Group
Organization:
National Cancer Institute NCI
Study Overview
Official Title:
Phase II Trial Of Perifosine In Locally Advanced Unresectable Or Metastatic Pancreatic Adenocarcinoma
Status:
COMPLETED
Status Verified Date:
2004-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
RATIONALE Perifosine may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
PURPOSE Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced unresectable or metastatic pancreatic cancer
PURPOSE Phase II trial to study the effectiveness of perifosine in treating patients who have locally advanced unresectable or metastatic pancreatic cancer
Detailed Description:
OBJECTIVES
Determine the activity of perifosine in terms of objective response in patients with locally advanced unresectable or metastatic pancreatic cancer
Determine the response duration progression-free survival and overall survival of patients treated with this drug
Determine the toxicity of this drug in these patients
OUTLINE This is a multicenter study
Patients receive oral perifosine every 6 hours for a total of 6 doses and then once daily in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 3 years
PROJECTED ACCRUAL A total of 35-84 patients will be accrued for this study within 21 months
Determine the activity of perifosine in terms of objective response in patients with locally advanced unresectable or metastatic pancreatic cancer
Determine the response duration progression-free survival and overall survival of patients treated with this drug
Determine the toxicity of this drug in these patients
OUTLINE This is a multicenter study
Patients receive oral perifosine every 6 hours for a total of 6 doses and then once daily in the absence of disease progression or unacceptable toxicity
Patients are followed every 3 months for 3 years
PROJECTED ACCRUAL A total of 35-84 patients will be accrued for this study within 21 months
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?:
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| ECOG-E1202 | None | None | None |